Biotech Thought Leadership: Making Complex Science Drive Business Results

The most common form of biotech marketing failure is silence. A company with genuinely important science, a credible team, and a real shot at a breakthrough — silent between milestones, invisible to the investors and talent and partners it needs to reach.

The logic is understandable: "we are scientists, not marketers," "we do not want to hype before we have results," "our work speaks for itself." But the work speaks for itself only to the 4,000 specialists who read the journals it appears in. Everyone else — the investor who could fund the next phase, the PhD student who could accelerate the research, the pharma partner who could license the platform — encounters silence and moves on.

The solution is not hype. It is translation.

The Three Audience Layers

Every scientific development can be communicated at three levels of depth, each targeting a different audience with a different function:

Layer 1: Expert level For HCPs, researchers, and scientific advisors who will engage with primary evidence. This is journal content, preprints, congress presentations, and detailed mechanism explainers. You are almost certainly already producing this. The gap is distribution — most of this content is never surfaced to the audiences who need to see it.

Layer 2: Investor level For VCs, LPs, family offices, and corporate development teams. They want to understand the platform differentiation, the mechanism of action in plain language, the market size, the competitive moat, and the de-risking milestones. They do not read papers — they read decks and follow LinkedIn and take calls with founders they already know are worth 30 minutes.

Layer 3: Public interest level For journalists, patient advocacy groups, recruits, and general stakeholders. At this level, the question is "what does this mean for patients?" or "why does this matter?" Science education, not science communication.

One research development — a positive Phase 2 read, a new collaboration, a patent grant — becomes three pieces of content: one for each layer. The underlying event is the same; the frame, depth, and language change entirely.

What the Founder and CSO Should Actually Post

The failure mode is posting nothing, because posting feels like self-promotion and self-promotion feels wrong.

The reframe: your audience needs to know you exist, what you believe, and why you are a credible person to build a biotech company. Sharing your thinking is not bragging — it is doing your job as a founder who needs capital, talent, and partnerships.

What works on LinkedIn for biotech founders:

Mechanism explainers in plain language: "I spent the last week explaining our mRNA delivery platform to three investors who are not scientists. Here is the version that finally worked." This is practical, specific, honest, and genuinely educational.

Journal reactions: When a new paper in your space publishes, your read on what it means and how it relates to your approach. Short, specific, positioned.

The build reality: What is hard about your specific scientific challenge. Not the polished pitch — the real friction. "We have been trying to solve [specific problem] for 14 months. Here is where we are." This is the content that builds the trust that makes investors take calls.

Milestone commentary: When a competitor reaches a milestone, or your own development reaches a stage, your reaction and what it means for the field — not just for your company.

Recruiting signal: "What we look for in a cell biologist at [company]." "Why we chose to be based in [city]." "What working on early-stage biotech is actually like." These reach recruits where they already are.

The Milestone Wave Model

Most biotech companies treat each development as a single announcement — a press release, a social post, and then silence until the next event.

A better model: every milestone becomes a 10-piece content wave over four weeks.

Week 0 (pre-announcement):

• —"We have something we will share next week" post (teaser — low-information, high-anticipation)

Week 1 (announcement):

• —Official announcement post (the fact and what it means)
• —Technical explainer (mechanism for the expert audience)
• —Plain-language explainer (what this means for the disease area)
• —Founder reaction post (personal, specific, honest about what the milestone required)

Weeks 2–3 (amplification):

• —Q&A post (answering the questions the announcement generated)
• —Related science thread (context from the broader field)
• —Team spotlight (who did the work and how)
• —Investor-frame post (what this milestone de-risks, what the next one is)

Week 4 (integration):

• —"What we learned from this phase" retrospective
• —Recruitment content pointing to the pipeline expansion this milestone enables

One event; ten pieces; four weeks of momentum. The company stays visible through the compounding of a single development.

The Translation Infrastructure

The bottleneck is usually the scientist's time, not the science. Founders and CSOs cannot spend 20 hours per month writing content — they are running a company.

The infrastructure that solves this: a monthly 60-minute session where the founder or CSO describes what has been happening, what they have been thinking about, and what they are focused on next. AI drafts 12–16 content pieces from that session. A specialist edits for accuracy (the scientist confirms the claims are accurate) and voice. The founder reviews drafts — 30 minutes total — and approves.

The founder's input is one hour monthly. The output is consistent, authentic, expert-level content that could not be generated without their thinking.

---

I build communication systems that make biotech science legible to the audiences it needs to reach. Let's talk about your pipeline.